RxDoctor Payments Data

Aimee Lopes, MD

Family Medicine · San Diego, CANPI 1851409593

Payments from drug & device makers

$5,404in general payments, 2019–2025

Across 250 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$3K
  • Gilead$1K
  • Theratechnologies Inc.$942
  • Johnson & Johnson$287
  • Janssen Products, LP$284

What the payments were for

  • Speaking & faculty fees$75014%
  • Food & beverage$4,52184%
  • Education$1332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company71$2,648
Gilead139$1,244
Theratechnologies Inc.4$942
Johnson & Johnson(2 entities)33$287
Janssen Products, LP3$284

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,404 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$17,973
Medicare patients
57
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala74$345,490
GenvoyaElviteg/Cob/Emtri/Tenof Alafen78$328,758
OdefseyEmtricitab/Rilpiviri/Tenof Ala47$180,202
DovatoDolutegravir Sodium/Lamivudine56$166,706
TivicayDolutegravir Sodium42$95,457
EliquisApixaban79$86,520
TriumeqAbacavir/Dolutegravir/Lamivudi16$80,725
PrezcobixDarunavir/Cobicistat21$59,243
JanuviaSitagliptin Phosphate41$56,017
JulucaDolutegravir/Rilpivirine13$46,023
DescovyEmtricitabine/Tenofov Alafenam19$45,471
TrulicityDulaglutide32$43,762
JardianceEmpagliflozin32$39,235
OzempicSemaglutide22$28,239
XareltoRivaroxaban17$21,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$1,244$719,719171 claims
Viiv Healthcare CompanyDovato, Tivicay, Triumeq, Juluca$2,648$388,911127 claims
Johnson & JohnsonPrezcobix, Xarelto$287$80,97538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →